HOWL Earnings Date: Nov 3, 2026 (Estimated) — Werewolf Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is HOWL's next earnings date?
Werewolf Therapeutics, Inc. (HOWL) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.22 on revenue of $18.3M.
How did HOWL do in its last earnings report?
In its most recent report on Jul 31, 2026 (Q2 2026), Werewolf Therapeutics, Inc. posted EPS of $0.08 versus the -$0.31 estimate, a beat of 125.8%. Revenue was $21.0M against a $21.0M estimate. The stock's 1-day post-earnings move was -29.4%.
How much does HOWL stock move after earnings?
HOWL beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.4% (up or down) in the day after earnings.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | Q2 2026 | -0.31 | 0.08 | +125.81% | $21.0M | ✅ Beat | -29.44% | -19.50% | +88.51% |
| 2026-05-07 | Q1 2026 | -0.30 | -0.28 | +6.67% | $0 | ✅ Beat | +9.68% | -12.48% | -38.40% |
| 2026-03-27 | Q4 2025 | -0.34 | -0.20 | +41.18% | $0 | ✅ Beat | -9.54% | +17.02% | -3.83% |
| 2025-11-04 | Q3 2025 | -0.39 | -0.36 | +7.69% | $0 | ✅ Beat | -7.63% | -11.45% | -29.93% |
| 2025-08-14 | Q2 2025 | -0.42 | -0.40 | +4.76% | $0 | ✅ Beat | -2.22% | -8.15% | +5.93% |
| 2025-05-08 | Q1 2025 | -0.43 | -0.40 | +6.98% | $0 | ✅ Beat | -5.54% | +7.49% | +54.18% |
| 2025-03-11 | Q4 2024 | -0.28 | -0.46 | -64.29% | $0 | ❌ Miss | +2.86% | -4.49% | -48.56% |
| 2024-11-07 | Q3 2024 | -0.41 | -0.38 | +7.32% | $0 | ✅ Beat | -8.20% | -15.98% | -26.23% |
Showing last 8 quarters.